Doctor of Philosophy

Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset

Retrieved on: 
Friday, January 13, 2023

Mr. West is a seasoned biopharma executive with over 25 years of experience in all levels of both public and private organizations leading and managing pipeline development across multiple therapeutic areas.

Key Points: 
  • Mr. West is a seasoned biopharma executive with over 25 years of experience in all levels of both public and private organizations leading and managing pipeline development across multiple therapeutic areas.
  • “With the addition of Terrence to the executive team, we are beginning to really establish our footprint in the Boston area,” stated Lisa Mahnke, M.D., PhD, Board Member and Chief Medical Officer of NMS S.r.l.
  • He previously served as Executive Director, Program Management at EMD Serono (a division of Merck KGaA), leading the development, global registration and commercialization of multiple oncology drugs.
  • Mr. West holds a MBA from the University of Phoenix, San Francisco and a BS in Chemistry from the University of Arizona.

Prahlad Singh Appointed to Board of Directors of Amphenol Corporation

Retrieved on: 
Thursday, January 12, 2023

Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol’s board of directors.

Key Points: 
  • Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol’s board of directors.
  • Dr. Singh is currently the President and Chief Executive Officer of PerkinElmer (NYSE: PKI) and brings more than twenty-five years of global leadership experience to Amphenol’s board.
  • He was promoted to President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and was appointed to its board of directors in 2019.
  • “Prahlad brings a wealth of experience to Amphenol, and we are excited to welcome him to Amphenol’s board of directors,” said R. Adam Norwitt, Amphenol’s President and CEO.

Velo3D Hires Dr. Robin Stamp as Director of Solutions Engineering

Retrieved on: 
Thursday, January 12, 2023

Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, today announced it has appointed Dr. Robin Stamp as Director of Solutions Engineering to help grow the adoption of Velo3D’s metal additive manufacturing technology with new customers and in new industries.

Key Points: 
  • Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, today announced it has appointed Dr. Robin Stamp as Director of Solutions Engineering to help grow the adoption of Velo3D’s metal additive manufacturing technology with new customers and in new industries.
  • View the full release here: https://www.businesswire.com/news/home/20230112005308/en/
    Robin Stamp, Director of Solutions Engineering at Velo3D (Photo: Business Wire)
    Dr.
  • Stamp has extensive experience leading teams in the research and development of additive manufacturing technology, which includes operating Velo3D’s fully integrated solution in production environments.
  • “In our industry, there aren’t many people with more experience using metal additive manufacturing technology in production environments than Robin,” said Dr. Greg Brown, Velo3D Vice President of Technology.

Neutron Therapeutics Announces Successful Generation of a Neutron Beam for BNCT at Shonan Kamakura General Hospital in Japan

Retrieved on: 
Thursday, January 12, 2023

Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.

Key Points: 
  • Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.
  • “Japan has been at the forefront of the modern, accelerator-based era of BNCT therapy and is the world leader in clinical BNCT research.
  • Neutron Therapeutics’ nuBeam® system produces the highest neutron flux available, leading to substantially shorter treatment times and improved patient experience.
  • The nuBeam® neutron source is not approved for commercial or clinical use by the FDA, PMDA, EMA or other regulatory body.

Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs

Retrieved on: 
Thursday, January 12, 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.
  • The platform leverages Charles River’s expertise in developing, manufacturing, and releasing more than 200 High Quality (HQ) and Good Manufacturing Practice- (GMP) compliant plasmid DNA batches.
  • eXpDNA supports a client’s plasmid DNA strategy by offering a proven, and standardized plasmid platform approach, suitable for plasmid DNA programs across various applications.
  • The eXpDNA plasmid manufacturing platform builds on Charles River’s established plasmid DNA CDMO capabilities and processes, fine-tuned over decades successfully supporting vaccine and advanced therapy clients through clinical trials and beyond.

Senda Biosciences Appoints Luke O’Neill, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 12, 2023

Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.
  • “Luke is a key addition to what is already a strong, effective leadership team,” said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering.
  • “Luke is a world-renowned immunologist who has contributed so much to the organization in his corporate governance and scientific advisory roles.
  • He holds a Ph.D. in pharmacology from the University of London and conducted postdoctoral research at the University of Cambridge, UK.

SURVEY: Middle-Income Americans Prepare for Possible Recession in 2023

Retrieved on: 
Thursday, January 12, 2023

The survey, in its third year, measures changes in the sentiments of middle-income families in the U.S. about their finances.

Key Points: 
  • The survey, in its third year, measures changes in the sentiments of middle-income families in the U.S. about their finances.
  • During the fourth quarter of 2022, 81% of middle-income households reported they are bracing for a possible recession in 2023, with 62% either planning or already taking steps to prepare.
  • Overall, Americans are pessimistic about the current economy and the year ahead.
  • “As middle-income families prepare for a possible recession this year, it’s more vital than ever that they take control of their personal finances by addressing debt, setting a budget and keeping spending in check,” said Glenn J. Williams, CEO of Primerica.

MTF Biologics Awards 2022 Extramural Research Grants

Retrieved on: 
Wednesday, January 11, 2023

MTF Biologics , a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has awarded more than $850,000 in funding to seven researchers across the nation through its 2022 Extramural Research Grants Program .

Key Points: 
  • MTF Biologics , a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has awarded more than $850,000 in funding to seven researchers across the nation through its 2022 Extramural Research Grants Program .
  • “We are so pleased that, even in the face of global economic uncertainty and ongoing challenges associated with the COVID-19 pandemic, MTF Biologics is able to continue giving back to the scientific and patient community through our Extramural Research Grants Program,” said Joe Yaccarino, president and CEO of MTF Biologics.
  • It is our hope that these studies will provide novel allograft-based options for a variety of clinical conditions.”
    2022 MTF Biologics Research Grants were awarded to the following:
    MTF BIOLOGICS EXTRAMURAL RESEARCH GRANT – ESTABLISHED INVESTIGATOR:
    MTF BIOLOGICS EXTRAMURAL RESEARCH GRANT– JUNIOR INVESTIGATOR:
    Mark Haber, M.D., Southern Orthopedics (Australia) “Allograft Augmentation of Irreparable Supraspinatus Tendon Tears: An Evaluation of Graft Healing Rate and Vascularity with Ultrasound And MRI, And Clinical Outcomes”)
    Meghan McCullough, M.D., Cedars Sinai Hospital “Use of allograft adipose matrix for small joint arthritis of the hand.
  • “We received many high quality grant proposals this year,” said Jeffrey Cartmell, Ph.D., director, Intellectual Property & Grants at MTF Biologics.

Woebot Health Names Trina Histon Vice President of Clinical Product Strategy

Retrieved on: 
Wednesday, January 11, 2023

Woebot Health today announced that it has appointed Trina Histon, PhD, as its Vice President of Clinical Product Strategy.

Key Points: 
  • Woebot Health today announced that it has appointed Trina Histon, PhD, as its Vice President of Clinical Product Strategy.
  • In the newly-created position, Histon will accelerate Woebot’s capabilities to integrate into care pathways and advance the software transformation of psychiatry, behavioral health and primary care.
  • View the full release here: https://www.businesswire.com/news/home/20230111005611/en/
    Trina Histon, PhD, Vice President of Clinical Product Strategy, Woebot Health (Photo: Business Wire)
    Histon’s expertise in embedding and deploying digital health solutions in care delivery spans more than two decades.
  • Before joining Woebot Health, Histon was a Senior Principal Consultant in Kaiser Permanente’s Care Management Institute (CMI).

SmartSense by Digi Accelerates Market Momentum Ahead of NRF 2023 Retail’s Big Show

Retrieved on: 
Wednesday, January 11, 2023

SmartSense by Digi®, part of Digi International (NASDAQ: DGII, www.digi.com ) and a leading global provider of Internet of Things (IoT) connectivity solutions, today announced a series of notable milestones signifying dynamic market momentum ahead of NRF 2023 Retail’s Big Show event.

Key Points: 
  • SmartSense by Digi®, part of Digi International (NASDAQ: DGII, www.digi.com ) and a leading global provider of Internet of Things (IoT) connectivity solutions, today announced a series of notable milestones signifying dynamic market momentum ahead of NRF 2023 Retail’s Big Show event.
  • “The momentum generated throughout 2022 marks a critical step forward for the future of SmartSense by Digi,” said Guy Yehiav, President of SmartSense by Digi.
  • Executive Leadership Shift: In February 2022, Digi International named renowned B2B enterprise software veteran Guy Yehiav as President of its SmartSense by Digi division.
  • SmartSense by Digi will unveil its new IoT Sensing as a Service open platform during a live presentation at NRF 2023 Retail’s Big Show on Jan. 15-17 in New York, NY.